NovaBay Pharmaceuticals (NBY) Debt to Equity (2016 - 2025)
NovaBay Pharmaceuticals (NBY) has disclosed Debt to Equity for 8 consecutive years, with $0.13 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity rose 182.41% to $0.13 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.13, a 182.41% increase, with the full-year FY2024 number at -$0.5, changed N/A from a year prior.
- Debt to Equity was $0.13 for Q3 2025 at NovaBay Pharmaceuticals, up from $0.03 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $6.08 in Q1 2024 to a low of -$1.06 in Q2 2024.
- A 4-year average of $0.51 and a median of $0.04 in 2024 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: crashed 867.12% in 2024, then surged 182.41% in 2025.
- NovaBay Pharmaceuticals' Debt to Equity stood at $0.01 in 2021, then skyrocketed by 1648.2% to $0.18 in 2023, then tumbled by 379.19% to -$0.5 in 2024, then skyrocketed by 126.66% to $0.13 in 2025.
- Per Business Quant, the three most recent readings for NBY's Debt to Equity are $0.13 (Q3 2025), $0.03 (Q2 2025), and $0.01 (Q1 2025).